Cybin Announces Closing of $175 Million Registered Direct Offering

Core Insights - Cybin Inc. has successfully closed a registered direct offering of 22,277,750 common shares, indicating strong investor interest and capital raising capabilities [1] Company Overview - Cybin Inc. is a Phase 3 clinical stage neuropsychiatry company focused on transforming mental healthcare through proprietary drug discovery platforms and innovative delivery systems [1]